KDR

ENSG00000128052
Target class
Kinase
Chromosome
4
Approved drugs
15
Clinical candidates (approved and in development)
75

Approved drugs
15
ClinGen gene-disease validity
Definitive
Clinical candidates (approved and in development)
75

Chemical probe available
Yes

Target name
KDR
Gene name
Kinase insert domain receptor
Gene symbol
KDR
Protein name
Vascular endothelial growth factor receptor 2 (VEGFR-2) (EC 2.7.10.1) (Fetal liver kinase 1) (FLK-1) (Kinase insert domain receptor) (KDR) (Protein-tyrosine kinase receptor flk-1) (CD antigen CD309)

  • FLK1
  • VEGFR
  • VEGFR2
  • CD309

Gene biotype
Protein coding
Gene family
Receptor tyrosine kinases|CD molecules|V-set domain containing|I-set domain containing
Target class
Kinase
Target type
Human gene

Tissues expressed in
52
Protein localisation evidence grade
Approved
Highest tissue expression
80.12
Tissue specificity (Gini)
0.553
Tissue specificity (tau)
0.808

KEGG gene identifiers
  • hsa:3791
Protein interaction confidence
0.865438
Protein interaction partners
153

  • R-HSA-194306
  • R-HSA-195399
  • R-HSA-216083
  • R-HSA-4420097
  • R-HSA-5218921
  • R-HSA-9673768
  • R-HSA-9856530

End position
55125595
Start position
55078476
Chromosome
4
Strand
Reverse

Ensembl gene ID
ENSG00000128052
HGNC ID
HGNC:6307
www.genenames.org
NCBI Gene ID
3791
UniProt ID
P35968

  • Cell junction . Endoplasmic reticulum . Cell membrane . Note=Localized with RAP1A at cell-cell junctions (By similarity). Colocalizes with ERN1 and XBP1 in the endoplasmic reticulum in endothelial cells in a vascular endothelial growth factor (VEGF)-dependent manner (PubMed:23529610). .
  • SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane
  • Single-pass type I membrane protein. Cytoplasm. Nucleus. Cytoplasmic vesicle. Early endosome. Note=Detected on caveolae-enriched lipid rafts at the cell surface. Is recycled from the plasma membrane to endosomes and back again. Phosphorylation triggered by VEGFA binding promotes internalization and subsequent degradation. VEGFA binding triggers internalization and translocation to the nucleus.
  • SUBCELLULAR LOCATION: [Isoform 2]: Secreted .
  • SUBCELLULAR LOCATION: [Isoform 3]: Secreted.
  • Connecting piece
  • Cytosol
  • Mid piece
  • Nuclear membrane
  • Principal piece
  • Vesicles

Tissue specificity (tau)
0.80837
Expression inequality (Gini)
0.552748

Expression in transcripts per million

Thyroid
80.12
Uterus
78.64
Adipose - Visceral (Omentum)
73.72
Lung
50.77
Breast - Mammary Tissue
47.42

Expression in transcripts per million

  • Thyroid80.12
  • Uterus78.64
  • Adipose - Visceral (Omentum)73.72
  • Lung50.77
  • Breast - Mammary Tissue47.42
  • Adipose - Subcutaneous44.87
  • Fallopian Tube40.76
  • Nerve - Tibial36.29
  • Cervix - Endocervix34.27
  • Cervix - Ectocervix25.65
  • Prostate23.22
  • Esophagus - Muscularis21.34
  • Pituitary20.56
  • Artery - Coronary19.33
  • Esophagus - Gastroesophageal Junction18.06
  • Bladder18.06
  • Artery - Tibial17.64
  • Kidney - Cortex16.48
  • Adrenal Gland16.06
  • Vagina15.29
  • Kidney - Medulla12.92
  • Heart - Atrial Appendage11.76
  • Small Intestine - Terminal Ileum11.26
  • Stomach11.18
  • Heart - Left Ventricle10.83

And 29 more, listed on the interactive page.

And 7 more, listed on the interactive page.

  • decreased appetite

    Effects

    • Inhibition/Decrease/Downregulation

    Studies

    • clinical

    Biological samples

    • CNS
    PubMed 38773351
    pubmed.ncbi.nlm.nih.gov

  • myocardial hypoperfusion

    Effects

    • Inhibition/Decrease/Downregulation

    Studies

    • clinical

    Biological samples

    • CV
    PubMed 38773351
    pubmed.ncbi.nlm.nih.gov

  • Increased, Developmental Defects

    Effects

    • Inhibition/Decrease/Downregulation

    Studies

    • cell-based
    Evidence source
    aopwiki.org

  • rash

    Effects

    • Inhibition/Decrease/Downregulation

    Studies

    • clinical

    Biological samples

    • skin
    PubMed 38773351
    pubmed.ncbi.nlm.nih.gov

  • haemorrhage

    Effects

    • Inhibition/Decrease/Downregulation

    Studies

    • clinical

    Biological samples

    • CV
    PubMed 38773351
    pubmed.ncbi.nlm.nih.gov

  • aneurysm

    Effects

    • Inhibition/Decrease/Downregulation

    Studies

    • clinical

    Biological samples

    • CV
    PubMed 38773351
    pubmed.ncbi.nlm.nih.gov

  • heart disease

    Studies

    • preclinical: Highly important for the heart and vasculature based on findings in genetically modified or kinase-inhibitor-treated mice. Role of kinase in heart/vasculature: Crucial in angiogenesis and the heart’s response to pressure overload; antihypertensive effects

    Biological samples

    • cardiovascular system
    PubMed 21283106
    pubmed.ncbi.nlm.nih.gov

  • nausea

    Effects

    • Inhibition/Decrease/Downregulation

    Studies

    • clinical
    PubMed 38773351
    pubmed.ncbi.nlm.nih.gov

  • vomiting

    Effects

    • Inhibition/Decrease/Downregulation

    Studies

    • clinical

    Biological samples

    • GI
    PubMed 38773351
    pubmed.ncbi.nlm.nih.gov

  • fatigue

    Effects

    • Inhibition/Decrease/Downregulation

    Studies

    • clinical
    PubMed 38773351
    pubmed.ncbi.nlm.nih.gov

  • proteinuria

    Effects

    • Inhibition/Decrease/Downregulation

    Studies

    • clinical

    Biological samples

    • renal
    PubMed 38773351
    pubmed.ncbi.nlm.nih.gov

  • Hypertension

    Effects

    • Inhibition/Decrease/Downregulation

    Studies

    • clinical

    Biological samples

    • CV
    PubMed 38773351
    pubmed.ncbi.nlm.nih.gov

  • regulation of catalytic activity

    • biochemical: NVS_ENZ_hVEGFR2, is one of one assay component(s) measured or calculated from the NVS_ENZ_hVEGFR2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.
    • biochemical: NVS_ENZ_hVEGFR2, is one of one assay component(s) measured or calculated from the NVS_ENZ_hVEGFR2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.

    Biological samples

    • cell-free
    Evidence source
    www.epa.gov

Related records

Trials (4,768)

Drugs (83)